2 min read
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A patient either lives or does not. In psychiatric drug development, the endpoints are almost never so crisp. In PTSD trials in...
2 min read
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision followed a June advisory committee meeting in which panelists voted nine to two that the data had not shown MDMA was effective, and ten to...
2 min read
Developing advanced therapies for neurology is often described as a “perfect storm of complexity.” These studies face scientific, operational, and ethical challenges that require careful planning from the earliest stages.
2 min read
In life, specialized knowledge is required when guesswork is not an option.
4 min read
2 min read
Developing therapies for neurological diseases represents one of the most challenging frontiers in modern biotechnology. With subjective clinical assessments, high variability in outcomes, and substantial investment requirements, neurology programs face...
4 min read
In the rapidly evolving field of circulating tumor DNA research, being on the front lines of clinical trials offers unparalleled insights into the future of cancer care. As Dr. Gabriela Rosu, Veristat’s Vice President, Global Medical Affairs, observes,...
4 min read
The promise of circulating tumor DNA for early cancer detection comes with a complex paradox: the very sensitivity that makes ctDNA valuable for catching cancer early also raises concerns about overdiagnosis and overtreatment. As Dr. Gabriela Rosu,...
1 min read
Learn how our neuroscience team partner with sponsors across multiple therapeutic areas to accelerate trial success in complex neurological and psychiatric conditions. Our collaborative efforts have supported successful marketing applications,...
3 min read
The promise of circulating tumor DNA (ctDNA) extends far beyond simply detecting cancer; it also holds potential for personalized treatment. As Dr. Gabriela Rosu, Veristat’s Vice President, Global Medical Affairs, recently explained, "If we know that...